Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001) Meeting Abstract
| Authors: | Powles, T.; Yu, E. Y.; Iyer, G.; Campbell, M. T.; Loriot, Y.; De Santis, M.; O'Donnell, P. H.; Burgess, E. F.; Necchi, A.; Krieger, L. E. M.; Matsubara, N.; Koshkin, V. S.; Zhang, W.; Ichimaru, M.; Galsky, M. D. |
| Abstract Title: | Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001) |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.TPS594 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS594 -- Source: Cinahl |
